Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Daiichi Sankyo
Covington
Moodys
AstraZeneca
Baxter
Fuji
Citi
Medtronic

Generated: November 20, 2018

DrugPatentWatch Database Preview

Cisatracurium besylate - Generic Drug Details

« Back to Dashboard

What are the generic sources for cisatracurium besylate and what is the scope of cisatracurium besylate freedom to operate?

Cisatracurium besylate is the generic ingredient in four branded drugs marketed by Accord Hlthcare, Fresenius Kabi Usa, Hospira Inc, Jiangsu Hengrui Med, Sandoz Inc, and Abbvie, and is included in eleven NDAs. Additional information is available in the individual branded drug profile pages.

There are nine drug master file entries for cisatracurium besylate. Five suppliers are listed for this compound.

Pharmacology for cisatracurium besylate
Synonyms for cisatracurium besylate
(1R-cis,1'R-cis)-2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium] bisbenzenesulfonate
(1R-cis,1'R-cis)-Atracurium besylate
(1R,1'R,2R,2'R)-2,2'-((pentane-1,5-diylbis(oxy))bis(3-oxopropane-3,1-diyl))bis(1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium) benzenesulfona
(1R,1'R,2R,2'R)-2,2'-((pentane-1,5-diylbis(oxy))bis(3-oxopropane-3,1-diyl))bis(1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium) benzenesulfonate
(1R,1'R,2R,2'R)-2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium] bisbenzenesulfonate
(1R,1'R,2R,2'R)-atracurium besylate
(1R,2R)-1-[(3,4-dimethoxyphenyl)methyl]-2-(3-{[5-({3-[(1R,2R)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl]propanoyl}oxy)pentyl]oxy}-3-oxopropyl)-6,7-dimethoxy-2-methyl-1,2,3
(1R,2R)-2-(2-Carboxyethyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-veratrylisoquinolinium benzenesulfonate, pentamethylene ester
51 W89
51W89
80YS8O1MBS
96946-42-8
AC1L1XZG
AC1Q22ND
AKOS026750111
Atracurium besylate 1R-cis,1R'-cis form
benzenesulfonate; 5-[3-[(1R,2R)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[(1R,2R)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H
Besilate de cisatracurium
Besilato de cisatracurio
C53H72N2O12.2(C6H5O3S)
C53H72N2O12.2C6H5O3S
CAS-64228-81-5
CCG-221271
CHEBI:3721
CHEMBL1200641
Cisatracurii besilas
Cisatracurium
Cisatracurium (besylate)
Cisatracurium besilate
Cisatracurium besilate (INN)
Cisatracurium besilate [INN]
Cisatracurium besilate, EuropePharmacopoeia (EP) Reference Standard
Cisatracurium besylate (Nimbex)
Cisatracurium besylate (USAN)
Cisatracurium besylate [USAN:BAN]
Cisatracurium besylate [USAN]
Cisatracurium Besylate Preservative Free
Cisatracurium besylate, United States Pharmacopeia (USP) Reference Standard
cisatracurium besylate(usan)
cisatracurium dibenzenesulfonate
Cisatracurium for peak identification, EuropePharmacopoeia (EP) Reference Standard
Cisatracurium for system suitability, EuropePharmacopoeia (EP) Reference Standard
Cisatracurium-Kation
CS-2471
D00759
D08ALK
DB00565
FT-0657467
HY-13596
Isoquinolinium, 2,2'-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, dibenzenesulfonate, (1R-(1alpha,2alpha(1'R(sup *),2'R(sup *))))-
KS-00000FXO
LS-178337
MolPort-003-987-490
N769
NCGC00017127-01
Nimbex
Nimbex (TN)
Nimbex Forte
NIMBEX PRESERVATIVE FREE
Nimbium
s2113
SCHEMBL40669
TL8006016
UNII-40AX66P76P component XXZSQOVSEBAPGS-DONVQRBFSA-L
UNII-80YS8O1MBS
UNII-Y78PS7MEDE component XXZSQOVSEBAPGS-DONVQRBFSA-L
W-60404
XXZSQOVSEBAPGS-DONVQRBFSA-L
Z2216208615

US Patents and Regulatory Information for cisatracurium besylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hospira Inc CISATRACURIUM BESYLATE cisatracurium besylate INJECTABLE;INJECTION 203236-002 Mar 30, 2018 AP RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sandoz Inc CISATRACURIUM BESYLATE PRESERVATIVE FREE cisatracurium besylate INJECTABLE;INJECTION 200154-002 Feb 3, 2012 AP RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Hospira Inc CISATRACURIUM BESYLATE cisatracurium besylate INJECTABLE;INJECTION 203236-001 Mar 30, 2018 AP RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Abbvie NIMBEX PRESERVATIVE FREE cisatracurium besylate INJECTABLE;INJECTION 020551-003 Dec 15, 1995 AP RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Abbvie NIMBEX cisatracurium besylate INJECTABLE;INJECTION 020551-001 Dec 15, 1995 AP RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for cisatracurium besylate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie NIMBEX cisatracurium besylate INJECTABLE;INJECTION 020551-001 Dec 15, 1995 ➤ Sign Up ➤ Sign Up
Abbvie NIMBEX PRESERVATIVE FREE cisatracurium besylate INJECTABLE;INJECTION 020551-003 Dec 15, 1995 ➤ Sign Up ➤ Sign Up
Abbvie NIMBEX PRESERVATIVE FREE cisatracurium besylate INJECTABLE;INJECTION 020551-002 Dec 15, 1995 ➤ Sign Up ➤ Sign Up
Abbvie NIMBEX PRESERVATIVE FREE cisatracurium besylate INJECTABLE;INJECTION 020551-002 Dec 15, 1995 ➤ Sign Up ➤ Sign Up
Abbvie NIMBEX PRESERVATIVE FREE cisatracurium besylate INJECTABLE;INJECTION 020551-003 Dec 15, 1995 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Daiichi Sankyo
Covington
Moodys
AstraZeneca
Baxter
Fuji
Citi
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.